China Approves First CAR T Therapy for a Solid Tumor

China’s National Medical Products Administration has approved satricabtagene autoleucel, making it the first CAR T-cell therapy approved for a solid tumor.

The therapeutic modality is an autologous CAR T-cell therapy targeting Claudin18.2, a tight-junction protein with limited expression in normal tissues but elevated expression in several gastrointestinal tumors, including gastric cancer.  The product, also known as satri-cel or CT041, has been approved in China for patients with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy.

The approval is supported by the randomized phase 2 CT041-ST-01 trial, which compared satri-cel with treatment of physician’s choice in previously treated advanced gastric or gastroesophageal junction cancer. Results showed a progression-free survival and overall survival benefit for satri-cel. In data presented at the 2025 ASCO Annual Meeting, median progression-free survival in the intent-to-treat population was 3.25 months with satri-cel versus 1.77 months with physician’s choice treatment, while median overall survival was 7.92 months versus 5.49 months. Source

Wearables Flag CAR T Toxicity Before Standard Monitoring

Wearable devices may help clinicians detect cytokine release syndrome earlier in patients receiving CAR T-cell therapy for relapsed or refractory multiple myeloma, according to a pilot study.

The study focused on patients receiving the autologous BCMA-directed CAR T-cell therapies idecabtagene vicleucel or ciltacabtagene autoleucel. The devices continuously collected skin and axillary temperature, heart rate, oxygen saturation, respiratory rate, and motion, while blood samples were analyzed for cytokine changes linked to CAR T activation and CRS.

Temperature emerged as the most immediately useful signal. A model combining axillary temperature with individual baseline values and a fixed threshold outperformed a simple 38°C fever threshold, which detected fewer CRS episodes and provided less lead time.

The researchers also found that cytokine changes tracked physiologic signals. Interferon gamma rose in patterns that mirrored CRS onset, with earlier increases after ide-cel and later peaks after cilta-cel. IFN-γ correlated with daily temperature measurements and emerged as a candidate biomarker that could be combined with wearable monitoring in future prediction models.

The authors argue that wearable monitoring could eventually support outpatient CAR T pathways, reducing hospital stays and improving access for patients who live far from specialized cancer centers. Source

Gene Therapy Shows Promise for Fatal Childhood Liver Disease

A liver-targeted gene therapy has rescued key features of a fatal childhood liver disease in mice, offering preclinical proof of concept for a potential treatment for arthrogryposis, renal dysfunction, and cholestasis syndrome.

ARC syndrome is a rare inherited disorder usually caused by defects in VPS33B or VIPAS39, genes that help regulate intracellular trafficking and liver cell polarity. In the liver, loss of VPS33B disrupts bile canaliculi and impairs bile flow, leading to cholestasis, progressive liver damage, fibrosis, and early death. Most affected children die within the first year of life, and there are currently no effective curative treatments.

In the study, researchers at University College London and Great Ormond Street Hospital tested in vivo lentiviral gene therapy designed to restore VPS33B expression in liver cells. Treated animals showed improved survival after disease exacerbation with a cholic acid diet: about 80 percent survived compared with 33 percent of mock-treated mice. They also showed improved growth, lower alkaline phosphatase, normalization or near-normalization of several lipid and bile-related biomarkers, reduced fibrosis, and partial restoration of bile canaliculi architecture.

The treatment was delivered with transient depletion of liver macrophages using clodronate liposomes, a strategy intended to improve lentiviral delivery to hepatocytes. The authors suggest that corrected cells may have gained a competitive advantage during liver regeneration, helping repopulate the liver over time.

“Our findings are important because it provides proof-of-concept that gene therapy could become a realistic treatment for ARC syndrome and potentially other inherited liver diseases that currently have few or no effective options,” said lead author Claudiu Cozmescu, of the UCL Great Ormond Street Institute of Child Health, in the release. Source

Serapha Bio to Go Public Through Boundless Bio Merger

Boundless Bio and Serapha Bio have agreed to merge in an all-stock transaction that will take Serapha public and fund development of its lead in vivo base editing program.

The transaction is supported by a concurrent $230 million private placement.

Serapha’s lead candidate, SERP-01, is an investigational in vivo base editing therapy designed to correct the SERPINA1 E342K mutation, also known as the PiZ mutation, which causes the most severe form of alpha-1 antitrypsin deficiency. The therapy aims to restore production of functional M-AAT while reducing toxic Z-AAT accumulation, potentially addressing both the lung and liver manifestations of the disease with a single administration.

SERP-01 was licensed from YolTech Therapeutics in June 2026. The program, developed as YOLT-202 in Greater China, is being evaluated in an investigator-initiated trial at Renji Hospital in Shanghai. Serapha said proof-of-concept data have shown restoration of serum AAT to normal levels. Source 

Legend Biotech Prices $226 Million Public Offering

Legend Biotech has priced an underwritten public offering expected to raise approximately $226 million in gross proceeds, before underwriting discounts, commissions, and other estimated expenses.

The company, which develops and markets the BCMA-targeted CAR T-cell therapy Carvykti with Johnson & Johnson, said it will offer 7.7 million American Depositary Shares at $29.35 per ADS. Each ADS represents two ordinary shares of Legend Biotech.

The financing comes as Legend continues to build around Carvykti, a one-time autologous CAR T-cell therapy for relapsed or refractory multiple myeloma. 

In a separate recent update, the company reported early clinical proof-of-concept data for LB2501, a potential first-in-class in vivo CD19/CD20 dual-targeting CAR T-cell candidate for relapsed or refractory B-cell non-Hodgkin lymphoma. Source

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

I have read and understand the Privacy Notice*

Subscribe